68Ga-Pentixafor PET/CT–Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18F-FDG–Based Response
68 Ga-Pentixafor PET/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and 18 F-FDG PET/CT-based criteria.
Authors
- Man Updesh Singh Sachdeva (ORCID: https://orcid.org/0000-0002-4406-8299)
- Baljinder Singh (ORCID: https://orcid.org/0000-0001-8464-7765)
- Harneet Kaur (ORCID: https://orcid.org/0000-0002-9107-363X)
- Ankit Watts
- Pankaj Malhotra (ORCID: https://orcid.org/0000-0003-1198-8491)
- Sreejesh Sreedharanunni (ORCID: https://orcid.org/0000-0003-2626-4154)
- Charanpreet Singh (ORCID: https://orcid.org/0000-0002-8189-8128)
- Rajender Kumar (ORCID: https://orcid.org/0000-0001-5098-5707)
- Suraj Kumar (ORCID: https://orcid.org/0000-0003-0583-3514)
Institutions
- Post Graduate Institute of Medical Education and Research (IN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1097/rlu.0000000000005731
- Citations
- 7
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.39